1. Scrip
  2. >>Therapy Areas
  3. >>Respiratory

Can Fresh INTEREST Breathe New Life Into Faron's Traumakine?

 
• By Kevin Grogan

Faron's ARDS drug looked doomed after the INTEREST study earlier this year but the Finnish group claims that a DNA analysis has identified some patients for whom Traumakine treatment could potentially be effective.

Diver
Faron dives deep for positive data • Source: Shutterstock

Faron Pharmaceuticals Oy has seen its stock jump after the Finland-headquartered group identified a subgroup of respiratory distress syndrome (ARDS) patients from a failed late-stage trial who may benefit from Traumakine (interferon-beta 1a).

The firm's prospects for Tramakine looked extremely bleak in May when Faron reported top-line data showing that the drug failed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

More from Therapy Areas

With ACIP Upheaval, Merck & Co. Among Those Left In A Lurch

 
• By Jessica Merrill and Bridget Silverman

Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By Andy Smith

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.